Protein tyrosine phosphatase non-receptor type 1 (PTPN1)
Protein tyrosine phosphatase non-receptor type 1 (PTPN1), commonly known as protein tyrosine phosphatase 1B (PTP1B), is a non-receptor protein tyrosine phosphatase that functions as a key negative regulator of signaling pathways mediated by receptor tyrosine kinases.
Protein tyrosine phosphatase non-receptor type 1 (PTPN1), commonly known as protein tyrosine phosphatase 1B (PTP1B), is a non-receptor protein tyrosine phosphatase that functions as a key negative regulator of signaling pathways mediated by receptor tyrosine kinases. In the contexts provided, it is described as a major modulator of insulin and Leptin (LEP) signaling, and therefore as an important molecular target in type 2 diabetes, obesity, and broader metabolic dysfunction. By attenuating these pathways, PTP1B can contribute to insulin resistance and impaired metabolic homeostasis.
Recent research also highlights a more complex role for PTP1B in immune and inflammatory biology. In myeloid cells, it has been linked to monocyte and macrophage activation, with implications for diabetic retinopathy and retinal neurodegeneration. This broader biology has made PTP1B a continuing focus of drug discovery efforts, especially for selective inhibitors that could improve glucose homeostasis and metabolic signaling without unacceptable off-target effects.
Where the papers sit
13 papers from the last 6 months study Protein tyrosine phosphatase non-receptor type 1 (PTPN1) directly · updated from PubMed 10 Nov 2026
Study type 0 clinical trials · 3 human data · 10 preclinical
Themes 3 themes · 1 new direction
-
Phosphatase Inhibitors in Cancer
Allosteric phosphatase inhibitors are being developed to disrupt RAS-driven and gastric cancer signaling. SHP2 and PTP1B programs repeatedly connect inhibition with PI3K/AKT, STAT3, migration, apoptosis and broader antiproliferative effects. Selective small molecules are advancing alongside macrocyclic ligands and computationally guided natural-product leads. The main open issue is whether multi-pathway activity can translate into selective antitumor efficacy.
5 papers · 38.5%
-
PTP1B Inhibitor Discovery
PTP1B inhibition is being pursued across glucose control and breast cancer. Cholic acid derivatives and dual DPP-4/PTP1B inhibitors aim to improve hypoglycemic activity, while plant extracts provide additional enzyme-inhibitory leads. In breast cancer, p-propoxybenzoic acid is linked to PTP1B inhibition and reduced DMBA-associated disease. The field is moving toward multi-target and structure-guided inhibitor development.
4 papers · 30.8%
-
PTP1B in Inflammatory Disease
PTP1B is being linked to inflammatory and stress-related injury across the brain, retina and metabolic disease. Inhibition is explored for Alzheimer’s disease and diabetic retinal neurodegeneration, where oxidative stress, myeloid signaling and apoptosis recur. miR-329-3p adds a biomarker and neuroprotection angle in ischemic stroke, while GLP-1R and IL-17A targeting addresses obesity-associated leukemia. The cluster supports PTP1B as a disease-modifying axis but does not establish one unified treatment strategy.
4 papers · 30.8%
PTP1B can serve as a noninhibitory proximity-recruitment handle rather than only as an enzyme to inhibit
The function-based screening study of PTP1B using bead-displayed macrocycles 42504525Jul challenges the assumption, shared by the other papers, that PTPN1/PTP1B is useful chiefly when its phosphatase activity is blocked. It identified macrocyclic ligands that engage PTP1B without inhibiting it and demonstrated a screening strategy intended to recruit the enzyme for chemically induced proximity and other functional manipulations. This recasts PTP1B from a conventional inhibitory drug target into a programmable molecular component whose preserved activity can be exploited.
Papers
The 13 papers from the last 6 months that study Protein tyrosine phosphatase non-receptor type 1 (PTPN1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Phosphatase Inhibitors in Cancer (5)
- Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity of Sophoricoside Against Pancreatic Cancer. Chemistry & biodiversity · 30 Sept 2026 PMID 42814531
- Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593923
- Mechanistic evaluation of NSC 57774 as a SHP2 inhibitor in gastric cancer: Multi-pathway signaling modulation in vitro. PloS one · 30 Jul 2026 PMID 42531194
- Discovery of Noninhibitory Macrocyclic Ligands for Protein Tyrosine Phosphatase 1B Using a Function-Based, Iterative Screening Strategy. Journal of the American Chemical Society · 27 Jul 2026 PMID 42504525
- Allosteric PTP1B inhibition as a source of multi-mechanistic anti-tumor activity. Bioorganic chemistry · 19 Jun 2026 PMID 42320116
PTP1B Inhibitor Discovery (4)
- Interceptive effect of p-propoxybenzoic acid against DMBA-induced breast cancer in female sprague dawley rats through PTP1B inhibition. Medical oncology (Northwood, London, England) · 9 Nov 2026 PMID 43002335
- Bioactive Properties of Achillea biserrata M.Bieb. Extracts: Phytochemical Analysis, Antioxidant Activity, Target Enzyme Inhibition, and Cytotoxic Effects. Chemistry & biodiversity · 31 Aug 2026 PMID 42672901
- Structure-Based De Novo Design of Novel Dual DPP IV and PTP 1B Inhibitors (DDPI's). Chemistry & biodiversity · 30 Jun 2026 PMID 42378400
- Cholic acid derivatives as novel PTP1B inhibitors: Their synthesis, inhibition mechanism, and hypoglycemic effects. European journal of medicinal chemistry · 19 Jun 2026 PMID 42320200
PTP1B in Inflammatory Disease (4)
- Serum miR-329-3p as a potential biomarker for ischemic stroke: clinical association and in vitro neuroprotection via PTPN1. Metabolic brain disease · 19 Oct 2026 PMID 42895677
- Targeting the protein tyrosine phosphatase 1B signaling axis in Alzheimer's disease: Emerging therapeutic potential of ivermectin. Biochemical and biophysical research communications · 3 Sept 2026 PMID 42691626
- Targeting GLP-1R and IL-17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model. The Journal of clinical investigation · 23 Jun 2026 PMID 42334870
- Myeloid Cell Protein Tyrosine Phosphatase 1B Drives Retinal Neurodegeneration in Diabetic Mice. Diabetes · 21 May 2026 PMID 42166617
By study type
Human data, design not indexed (3)
- Serum miR-329-3p as a potential biomarker for ischemic stroke: clinical association and in vitro neuroprotection via PTPN1. Metabolic brain disease · 19 Oct 2026 PMID 42895677
- Discovery of Noninhibitory Macrocyclic Ligands for Protein Tyrosine Phosphatase 1B Using a Function-Based, Iterative Screening Strategy. Journal of the American Chemical Society · 27 Jul 2026 PMID 42504525
- Structure-Based De Novo Design of Novel Dual DPP IV and PTP 1B Inhibitors (DDPI's). Chemistry & biodiversity · 30 Jun 2026 PMID 42378400
Preclinical: animal, cell and lab studies (10)
- Interceptive effect of p-propoxybenzoic acid against DMBA-induced breast cancer in female sprague dawley rats through PTP1B inhibition. Medical oncology (Northwood, London, England) · 9 Nov 2026 PMID 43002335
- Multi-Omics and Computational Pharmacology Approach With Experimental Validation Reveals the Antiproliferative Activity of Sophoricoside Against Pancreatic Cancer. Chemistry & biodiversity · 30 Sept 2026 PMID 42814531
- Targeting the protein tyrosine phosphatase 1B signaling axis in Alzheimer's disease: Emerging therapeutic potential of ivermectin. Biochemical and biophysical research communications · 3 Sept 2026 PMID 42691626
- Bioactive Properties of Achillea biserrata M.Bieb. Extracts: Phytochemical Analysis, Antioxidant Activity, Target Enzyme Inhibition, and Cytotoxic Effects. Chemistry & biodiversity · 31 Aug 2026 PMID 42672901
- Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers. Journal of medicinal chemistry · 13 Aug 2026 PMID 42593923
- Mechanistic evaluation of NSC 57774 as a SHP2 inhibitor in gastric cancer: Multi-pathway signaling modulation in vitro. PloS one · 30 Jul 2026 PMID 42531194
- Targeting GLP-1R and IL-17A suppresses obesity-induced leukemia in an oncogenic PTPN11 mutation-driven model. The Journal of clinical investigation · 23 Jun 2026 PMID 42334870
- Cholic acid derivatives as novel PTP1B inhibitors: Their synthesis, inhibition mechanism, and hypoglycemic effects. European journal of medicinal chemistry · 19 Jun 2026 PMID 42320200
- Allosteric PTP1B inhibition as a source of multi-mechanistic anti-tumor activity. Bioorganic chemistry · 19 Jun 2026 PMID 42320116
- Myeloid Cell Protein Tyrosine Phosphatase 1B Drives Retinal Neurodegeneration in Diabetic Mice. Diabetes · 21 May 2026 PMID 42166617
Written from 13 PubMed abstracts, each one listed by PMID above. Published: 2026-07-08. Last written: 2026-09-02 by GPT. Drafted by language models from published abstracts; not medical advice.